StockData
Boston Scientific Corp logo

Boston Scientific Corp (BSX) stock

BSXNYSESurgical & Medical Instruments & ApparatusFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 2, 2026Score 14/3048% below fair value
$43.03−0.66 (-1.51%)

Close on Nov 17, 2026Market cap $62.36BP/E 17.4Yield –

Boston Scientific operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

Boston Scientific's operating cash flow for the twelve months ending Jun 30, 2026 was $4.53B, up 5.7% year over year. For fiscal 2025 it was $4.53B, up 32.0% from the year before. Over ten years it grew 20.7% a year on average. The highest annual figure on record is $4.53B in fiscal 2025.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025$4.53B+32.0%
FY2024Dec 31, 2024$3.44B+37.2%
FY2023Dec 31, 2023$2.50B+64.0%
FY2022Dec 31, 2022$1.53B-18.4%
FY2021Dec 31, 2021$1.87B+24.0%
FY2020Dec 31, 2020$1.51B-17.9%
FY2019Dec 31, 2019$1.84B+492.3%
FY2018Dec 31, 2018$310.00M-78.3%
FY2017Dec 31, 2017$1.43B+20.6%
FY2016Dec 31, 2016$1.18B+71.1%
FY2015Dec 31, 2015$691.00M-45.5%
FY2014Dec 31, 2014$1.27B+14.3%
FY2013Dec 31, 2013$1.11B-13.3%
FY2012Dec 31, 2012$1.28B+27.0%
FY2011Dec 31, 2011$1.01B+210.2%
FY2010Dec 31, 2010$325.00M-61.1%
FY2009Dec 31, 2009$835.00M-31.3%
FY2008Dec 31, 2008$1.22B+30.2%
FY2007Dec 31, 2007$934.00M–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$1.47B+14.6%
Q1 FY2026Mar 31, 2026$348.00M-35.7%
Q4 FY2025Dec 31, 2025$1.36B-6.3%
Q3 FY2025Sep 30, 2025$1.34B+34.0%
Q2 FY2025Jun 30, 2025$1.29B+58.2%
Q1 FY2025Mar 31, 2025$541.00M+229.9%
Q4 FY2024Dec 31, 2024$1.46B+52.1%
Q3 FY2024Sep 30, 2024$1.00B+43.6%
Q2 FY2024Jun 30, 2024$813.00M+23.6%
Q1 FY2024Mar 31, 2024$164.00M-13.7%
Q4 FY2023Dec 31, 2023$957.00M+18.6%
Q3 FY2023Sep 30, 2023$698.00M+48.5%
Q2 FY2023Jun 30, 2023$658.00M+114.3%
Q1 FY2023Mar 31, 2023$190.00M–
Q4 FY2022Dec 31, 2022$807.00M+68.8%
Q3 FY2022Sep 30, 2022$470.00M+1.1%
Q2 FY2022Jun 30, 2022$307.00M-52.3%
Q1 FY2022Mar 31, 2022-$58.00M-120.4%
Q4 FY2021Dec 31, 2021$478.00M-29.0%
Q3 FY2021Sep 30, 2021$465.00M-27.7%
Q2 FY2021Jun 30, 2021$643.00M+139.0%
Q1 FY2021Mar 31, 2021$284.00M–
Q4 FY2020Dec 31, 2020$673.00M-2.7%
Q3 FY2020Sep 30, 2020$643.00M+28.1%
Q2 FY2020Jun 30, 2020$269.00M-7.9%
Q1 FY2020Mar 31, 2020-$77.00M-122.0%
Q4 FY2019Dec 31, 2019$692.00M+3542.1%
Q3 FY2019Sep 30, 2019$502.00M+0.2%
Q2 FY2019Jun 30, 2019$292.00M–
Q1 FY2019Mar 31, 2019$350.00M+81.3%
Q4 FY2018Dec 31, 2018$19.00M-97.2%
Q3 FY2018Sep 30, 2018$501.00M+10.8%
Q2 FY2018Jun 30, 2018-$403.00M-235.7%
Q1 FY2018Mar 31, 2018$193.00M–
Q4 FY2017Dec 31, 2017$684.00M+1.2%
Q3 FY2017Sep 30, 2017$452.00M–
Q2 FY2017Jun 30, 2017$297.00M–
Q1 FY2017Mar 31, 2017-$7.00M–
Q4 FY2016Dec 31, 2016$676.00M–
Q3 FY2016Sep 30, 2016-$31.00M–

More Boston Scientific figures

See a number that looks wrong?